Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 50,316 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Clear all
Active, not recruiting Phase 3 Interventional

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

NCT00734877
View directory record Official record
Conditions
Multiple Myeloma
Interventions
M-VTD-PACE, TT3-LITE Regimen (L-TT3)
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 1:19 AM EDT
Recruiting Not applicable Interventional

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

NCT06106477
View directory record Official record
Conditions
Breast Cancer
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 1:19 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Interventions
AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy

NCT03290677
View directory record Official record
Conditions
Lung Cancer
Interventions
Cryoablation, Biopsy
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 23, 2026, 1:19 AM EDT
Completed No phase listed Observational

Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

NCT03200977
View directory record Official record
Conditions
Lymphoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Lawrenceville, New Jersey • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Results available

Perfusion Assessment in Laparoscopic Left Anterior Resection

NCT01560377
View directory record Official record
Conditions
Rectal Cancer, Colon Cancer, Crohn's Disease, Polyp, Procidentia, Diverticulitis
Interventions
PINPOINT Endoscopic Fluorescence Imaging System
Device
Lead sponsor
Novadaq Technologies ULC, now a part of Stryker
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00062322
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 23, 2026, 1:19 AM EDT
Active, not recruiting Phase 2 Interventional Results available

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

NCT02392429
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chemotherapy, Computed Tomography, Cytarabine, Fluorothymidine F-18, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
11
States / cities
Rochester, Minnesota • St Louis, Missouri • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Educational Intervention - Improving Knowledge and Screening Rates for Colorectal Cancer

NCT03287453
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Educational Intervention, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
50 Years to 74 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 23, 2026, 1:19 AM EDT
Recruiting No phase listed Observational

Observational Study Protocol: LIVER-R

NCT06252753
View directory record Official record
Conditions
Hepatobiliary Cancers
Interventions
Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:19 AM EDT
Recruiting No phase listed Observational

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

NCT05011045
View directory record Official record
Conditions
Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, Secondary Central Nervous System Lymphoma
Interventions
Magnetic Resonance Imaging, Neurocognitive Assessment, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 23, 2026, 1:19 AM EDT
Not listed No phase listed Observational

Unveiling Patient Experiences in Testicular Cancer Clinical Trials

NCT05928377
View directory record Official record
Conditions
Testicular Cancer
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Phase 1 Interventional

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

NCT00413075
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
oral belinostat
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Phase 2 Interventional

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy

NCT00054522
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone
Dietary Supplement · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Buffalo, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 23, 2026, 1:19 AM EDT
Not listed No phase listed Observational

Early Prostate Cancer: Predicting Treatment Response

NCT03770351
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 23, 2026, 1:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT05626322
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Maplirpacept, Tafasitamab, Lenalidomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Ann Arbor, Michigan • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Phase 1 Interventional

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

NCT02549651
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
MEDI4736, tremelimumab, AZD9150
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
La Jolla, California • Baltimore, Maryland • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

NCT00003322
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, paclitaxel, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Phase 1Phase 2 Interventional

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

NCT00038831
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia
Interventions
Mylotarg, Fludarabine, Melphalan, Anti-thymocyte globulin, Stem cell transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 23, 2026, 1:19 AM EDT
Recruiting Early Phase 1 Interventional

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

NCT02446431
View directory record Official record
Conditions
Solid Tumor
Interventions
Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus
Drug
Lead sponsor
Miller Children's & Women's Hospital Long Beach
Other
Eligibility
12 Months to 31 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementing Fit Kit Colorectal Cancer (CRC) Screening in High Risk Populations

NCT04848051
View directory record Official record
Conditions
Colorectal Cancer
Interventions
CRC screening reminder, CRC Reminder & Short message, CRC Reminder and Navigation Program, CRC Reminder & CRC education
Behavioral
Lead sponsor
Yale University
Other
Eligibility
50 Years to 74 Years
Enrollment
3,127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 23, 2026, 1:19 AM EDT
Recruiting No phase listed Observational

A Multicenter Cancer Biospecimen Collection Study

NCT04510129
View directory record Official record
Conditions
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer
Interventions
OncoPrism™ assay
Diagnostic Test
Lead sponsor
Cofactor Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 23, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

NCT01588431
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 23, 2026, 1:19 AM EDT
Terminated Phase 2 Interventional Results available

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

NCT00843531
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
RAD001, erlotinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 23, 2026, 1:19 AM EDT